With the approval and clinical availability of BTK inhibitors, are you effectively managing the associated toxicities in your patients with lymphomas to get the most out of these agents?
A free resource guide for patients who are receiving BTK inhibitors, including information on FDA approvals, dosing, and potential side effects.
Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 renowned experts in hematologic malignancies.
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270
Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.